Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?

Group 1 - AngioDynamics (ANGO) has shown strong year-to-date performance, returning 9.2% compared to the Medical sector's average return of -5.6% [4] - The Zacks Consensus Estimate for AngioDynamics' full-year earnings has increased by 22.5% over the past 90 days, indicating improved analyst sentiment [4] - AngioDynamics holds a Zacks Rank of 1 (Strong Buy), suggesting it has characteristics to outperform the market in the near term [3] Group 2 - AngioDynamics is part of the Medical - Instruments industry, which consists of 85 companies and currently ranks 90 in the Zacks Industry Rank [6] - The Medical - Instruments industry has an average year-to-date loss of 8.9%, highlighting AngioDynamics' relative outperformance [6] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR has also outperformed its sector with an 18.8% return this year and a Zacks Rank of 2 (Buy) [5][7]